InflaRx to Present at Upcoming Investor Conferences
- ByBenzinga-
InflaRx N.V. (NASDAQ:IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that...
Symbol | Exchange | Currency |
|---|
InflaRx N.V. (NASDAQ:IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that...
Clinical-stage biopharmaceutical companyInflaRx N.V
InflaRx (IFRX)traded 9.9% down after hourson commencing an underwritten public offering of shares; for each common share purchased, an investor will also receive a warrant to...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 8.00 | 8.05 | 7.90 | +0.05 | +0.63% | 6.02M | Lagos | |||
| 160.00 | 160.00 | 160.00 | -10.00 | -5.88% | 1.04M | Lagos | |||
| 31.05 | 31.05 | 30.80 | +0.05 | +0.16% | 4.69M | Lagos | |||
| 24.90 | 25.40 | 24.70 | -0.40 | -1.58% | 66.50M | Lagos | |||
| 18.85 | 18.85 | 18.85 | -0.05 | -0.26% | 27.29K | Lagos | |||
| 0.66 | 0.00 | 0.00 | -0.01 | -1.49% | 73.55K | Lagos | |||
| 5.90 | 5.90 | 5.90 | -0.42 | -6.65% | 1.81K | Lagos | |||
| 8.05 | 8.00 | 7.90 | +0.20 | +2.56% | 11.74M | Lagos | |||
| 43.85 | 40.00 | 40.00 | +3.85 | +9.62% | 6.96M | Lagos | |||
| 0.20 | 0.00 | 0.00 | 0.00 | 0.00% | 0.00K | Lagos | |||
| 27.30 | 27.30 | 27.30 | +0.30 | +1.11% | 187.50K | Lagos | |||
| 86.00 | 86.00 | 86.00 | -7.00 | -7.53% | 102.73K | Lagos | |||
| 0.85 | 0.00 | 0.00 | +0.040 | +4.94% | 7.84M | Lagos | |||
| 67.50 | 67.50 | 67.50 | -7.25 | -9.70% | 170.89K | Lagos | |||
| 5.00 | 5.00 | 5.00 | 0.00 | 0.00% | 542.07K | Lagos |
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.